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ABSTRACT
Introduction: A post hoc analysis of three ran-
domized controlled trials of abatacept in
rheumatoid arthritis (RA) was conducted to
explore the effect of abatacept on fatigue in RA
and its correlation with other outcomes.
Methods: In this analysis of AGREE (early RA)
and AIM and ATTAIN (established RA), changes in
baseline fatigue (0–100 mm scale), pain, sleep
(AIM and ATTAIN only) and Disease Activity
Score (DAS) 28 (C-reactive protein; CRP) were
calculated at days 29, 85, and 169. Agreement
between improvements Cminimum clinically
importantdifferences (MCID) in fatigue and other
outcomes were evaluated using agreement statis-
tics (kappa) in each study and at each time point.
Results: Of 1536 patients (mean disease dura-
tion: 6.2 months [AGREE], 8.5 years [AIM],
12.2 years [ATTAIN]), mean (SE) decreases in
fatigue from baseline to day 169 with abatacept
were 28.9 (1.7), 25.3 (1.2), and 21.9 (1.6) in
AGREE, AIM, and ATTAIN, respectively, with
corresponding decreases of 16.0, 13.7, and 13.4
at day 29. Most patients (67.8%; 624/920)
reported improvements CMCID in fatigue with
abatacept at day 169; 79.2% (671/847) and
57.8% (388/671) reported improvements
CMCID in pain and sleep, respectively; 18.9%
(158/836) were in DAS28 (CRP) remission.
Agreement between improvement in fatigue
and other outcomes was low (kappa range
0.30–0.51 [pain], 0.14–0.26 [sleep], and
0.02–0.12 [DAS28 (CRP) remission]).
Conclusions: Abatacept resulted in rapid
improvements in fatigue and pain in patients
with RA. However, low agreement between
improvements in these outcomes indicates that
fatigue and other outcomes including pain and
sleep may represent different domains of
response.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoim-
mune disease that has a wide-ranging impact on
patients’ health-related quality of life [1]. Fatigue
and impairment of physical and mental func-
tioning can be direct or indirect consequences of
the inflammatory response and can significantly
compromise normal daily activity [1]. Patient-
reported outcomes (PROs) are important consid-
erations when optimizing treatment options, and
the assessment of PROs is recommended in the
evaluation of therapeutic agents for RA [2].
Despite recognition of the value of measuring
outcomes from the patient’s perspective [3, 4],
PROs often remain unaddressed [5].
Fatigue is reported by up to 80% of patients
with RA [6], and severe fatigue is highly preva-
lent [7]. Biologic disease-modifying antirheu-
matic drugs (DMARDs) have been reported to
reduce fatigue in RA. Treatment with abatacept,
a T cell costimulation modulator, has also
demonstrated clinically meaningful improve-
ments in fatigue in patients with RA, but the
onset of action of these effects on fatigue has
not been assessed [8–11].
The causes of fatigue in RA are not com-
pletely understood. Factors other than those
directly linked to inflammation and disease
activity are thought to be involved [12–14].
Although a recent systematic review showed no
correlation between fatigue and disease dura-
tion in RA, significant correlations were repor-
ted between fatigue and patient-reported pain
and disease activity (assessed using Disease
Activity Score (DAS) 28 [C-reactive protein;
CRP]), with pain as the main contributor [15].
The poor sleep quality experienced by many
patients with RA may also contribute to fatigue
[14], and disease activity has been found to
predict sleep disturbance [16]. Furthermore,
multidimensional modeling has shown that
disease activity leads to mood disturbance and
poor sleep quality, which in turn lead to fatigue
[14]. However, the factors underlying fatigue
and its interrelationship with other RA symp-
toms needs further investigation.
This post hoc analysis examined the effect and
the onset of effect of abatacept treatment on
fatigue in patients with RA from three different
randomized controlled trial (RCT) populations,
including methotrexate (MTX)-naı¨ve patients,
MTX inadequate responders (IRs), and tumor
necrosis factor-a (TNF)-IRs. Pain is a well-validated
PRO in RA and we considered it of interest to
compare treatment-related improvements in fati-
gue versus improvements in pain. Associations
between the effect of abatacept on fatigue and
pain, sleep, and DAS28 (CRP) were also explored.
METHODS
Study Design
A post hoc analysis of three abatacept RCTs was
conducted to evaluate the effect of treatment on
fatigue and the correlation with pain, sleep, and
DAS28 (CRP) outcomes. The trials were AGREE
(Abatacept study to Gauge Remission and joint
damage progression in MTX-naı¨ve patients with
Early Erosive RA; NCT00122382) in early RA [17],
AIM (Abatacept in Inadequate responders to
Methotrexate; NCT00048568) [18], and ATTAIN
(Abatacept Trial in Treatment of Anti-TNF INade-
quate responders; NCT00048581) in established
RA [19]. In AGREE, patients were either MTX naı¨ve
or had previous exposure to MTX, B10 mg/week
for B3 weeks [17]; in AIM, patients were MTX-IRs
[18] (C15 mg/week for C3 months, with a
stable dose for 28 days before enrollment); and in
ATTAIN, patients were inadequate responders to
the TNF inhibitors etanercept, infliximab, or both
after C3 months of treatment [19]. The RCTs
selected included largepatientpopulationsandthe
same PROs at the same time points. The studies
were conducted in accordance with the Declara-
tion of Helsinki, International Conference on
Harmonisation Guidelines for Good Clinical
Practice, and local regulations. An Institutional
Review Board or Independent Ethics Committee
approved the protocol and consent form at each
study site. Informed consent was obtained from all
patients for being included in the study. Study
designs, patient populations, and primary efficacy
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and safety results have been reported previously
[17–19].
In all three trials, patients were randomized to
receive either intravenous abatacept 10 mg/kg or
placebo every 28 days. All patients received con-
comitant MTX in the AGREE and AIM trials, and
patients continued concomitant DMARD medi-
cation at randomization in the ATTAIN trial.
Study Assessments
Assessments were conducted at baseline and at
days 29, 85, and 169. Fatigue and pain were asses-
sed using visual analog scales (VAS; 0–100 mm), in
which higher scores indicate worse symptoms.
Sleep was assessed using the 12-item Medical Out-
comes Study Sleep module (MOS-Sleep; score
0–100) in AIM and ATTAIN only. DAS28 (CRP) was
evaluated at multiple time points including those
when fatigue, pain, and sleep were assessed.
Improvements in fatigue Cminimum clinically
important differences (MCID) from baseline to day
169 were cross-tabulated with those for other out-
comes and with DAS28 (CRP) remission. MCIDs
were defined as pain and fatigue VAS score changes
from baseline B-10 mm [20], and sleep score
change from baseline B-6 mm. DAS28 (CRP)
remission was defined as DAS28 (CRP)\2.6.
Statistical Analysis
Data from each RCT were analyzed separately.
Mean changes from baseline in fatigue and pain
at each time point were determined using an
analysis of covariance model, with treatment as
a factor and baseline value as a covariate.
Agreement between reported improvements
CMCID in fatigue with those in pain and sleep,
and with attainment of DAS28 (CRP) remission
were evaluated using agreement statistics
(kappa) at baseline and at days 29, 85, and 169.
RESULTS
Analysis Population
Patient demographics and clinical characteris-
tics at baseline in the original RCTs (n = 1552)
[17–19] are shown in Table 1. Across the three
trials, data for this post hoc analysis were
available for a total of 1536 patients. Given the
design of the trials, mean disease duration of RA
for patients treated with abatacept varied from
6.2 months in AGREE to 8.5 and 12.2 years in
AIM and ATTAIN, respectively.
Baseline Fatigue and Other PROs
Slightly higher mean fatigue and pain scores at
baselinewereobserved in thepatientpopulationof
ATTAIN compared with those of the patient pop-
ulations of AGREE and AIM. Mean sleep scores at
baseline were similar in AIM and ATTAIN, and
DAS28 (CRP) scoreswerehigher forpatients in AIM
than for patients in ATTAIN and AGREE (Table 1).
Treatment Effect of Abatacept on Fatigue
Changes from baseline in fatigue score were
apparent by day 29 in each trial (Fig. 1a;
Table 2). At day 169, improvements in fatigue
CMCID with abatacept treatment were reported
by C60% of patients in AGREE, AIM, and
ATTAIN (Fig. 2a). Adjusted mean treatment
differences for abatacept versus placebo at day
169 were highest in the ATTAIN patient popu-
lation (Table 2).
Treatment Effect of Abatacept on Pain
Changes from baseline in pain scores were more
pronounced in patients with early disease
(AGREE) versus those seen in patients with longer
disease duration (AIM and ATTAIN; Fig. 1b); a
higher proportion of patients in AGREE versus
AIM or ATTAIN reported improvements in pain
CMCID with abatacept at day 169. Adjusted
mean treatment differences for change from
baseline in pain score for abatacept versus placebo
at day 169 were highest in ATTAIN (Table 2).
Association Between Changes in Fatigue
and Pain with Abatacept Treatment
Overall, most patients reporting improvements










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































day 169 also did so for pain (62.9%; 532/846;
Supplementary Fig. 1). Cross-tabulation indi-
cated a greater proportion of patients who
reported improvements in fatigue CMCID also
reported improvements in pain CMCID at day
169 in AGREE (68.6%) versus AIM (62.6%) or
ATTAIN (57.0%; Supplementary Fig. 1). Kappa
statistics indicated that agreement between the
proportions of patients with changes in fatigue
and pain CMCID following abatacept treatment
was low to moderate across the studies and time
points (kappa range 0.30–0.51; Table 3).
Association Between Changes in Fatigue
and Other Outcomes with Abatacept
Treatment
In AIM and ATTAIN, most patients reported
improvements in sleep CMCID with abatacept
Fig. 1 Adjusted mean
change from baseline
in fatigue (a) and pain
(b) score (VAS) over




at day 169: 57.4% (241/420; 95% CI 52.7, 62.1)
of patients in AIM and 58.6% (147/251; 95% CI
52.5, 64.7) of patients in ATTAIN. Agreement
(kappa statistics) between the proportion of
abatacept-treated patients with changes in fati-
gue and sleep CMCID at day 169 was low in
both studies at all time points (kappa range
0.14–0.26; Table 3). Cross-tabulation indicated
a corresponding 46.7 and 42.3% of patients in
AIM and ATTAIN, respectively, who reported
improvements in fatigue CMCID with abatacept
also reported improvements in sleep CMCID at
day 169.
Agreement (kappa statistics) between treat-
ment-related improvements in fatigue CMCID
and attainment of DAS28 (CRP) remission at
day 169 was very small (0.12 [AGREE], 0.04
[AIM], and 0.06 [ATTAIN]; Table 3). Cross-
tabulation indicated more patients in AGREE
than in AIM or ATTAIN who reported
improvement in fatigue CMCID also achieved
DAS28 (CRP) remission at day 169 (26.8, 12.3,
Table 2 Changes from baseline fatigue and pain scores over time in AGREE, AIM, and ATTAIN
AGREE AIM ATTAIN





66.2 (23.6) 64.5 (26.1) 63.4 (23.1) 65.9 (22.8) 73.8 (19.7) 72.2 (19.4)
Change from baseline fatigue score, adjusted mean (SE)




-6.67 (-10.32, -3.01) -4.80 (-8.29, -1.30) -7.14 (-11.69, -2.59)








67.1 (22.3) 67.1 (22.9) 63.6 (20.8) 66.4 (19.6) 70.4 (19.4) 67.9 (19.5)
Change from baseline pain score, adjusted mean (SE)




-6.21 (-10.45, -1.97) -12.75 (-16.97, -8.54) -18.66 (-24.74, -12.58)
Data shown are the score data available for the numbers of patients at each stage of the AGREE, AIM, and ATTAIN
studies
ABA abatacept, AMTD adjusted mean treatment difference, DMARD disease-modifying antirheumatic drug, MTX
methotrexate, PBO placebo, SD standard deviation, SE standard error
Rheumatol Ther
and 9.0% of patients in AGREE, AIM, and
ATTAIN, respectively).
DISCUSSION
This post hoc analysis of the AGREE, AIM, and
ATTAIN studies showed that treatment with
abatacept led to rapid improvements in fatigue
in the RA patient populations of three different
RCTs. Improvements in fatigue were associated
with improvements in pain, but less with
improvements in sleep and attainment of
DAS28 (CRP) remission.
Improvements in fatigue were reported
across all three RCTs and, as expected, treat-
ment response was higher in AGREE, in which
all patients were DMARD naı¨ve and randomized
to receive either abatacept plus MTX or placebo
plus MTX, than in the DMARD-experienced
populations of AIM and ATTAIN. Across all
three RCT populations, however, approximately
Fig. 2 Proportion of
patients reporting
improvements in fati-
gue (a) and pain
(b) CMCID at day
169 in AGREE, AIM,
and ATTAIN. MCID
for fatigue was deﬁned
as fatigue score change
from baseline
B-10 mm. MCID
for pain was deﬁned
































































































































































































































































































































































































































































































































































































































































































































half of the treatment effect of abatacept on
fatigue observed at day 169 was already appar-
ent by day 29, indicating a rapid onset of effi-
cacy and increasing benefit with continued
treatment, at least up to 6 months, irrespective
of disease duration or previous therapy.
Fatigue in RA is poorly understood and
appears to be related to a multitude of factors
including pain, sleep, and disease activity [13].
Fatigue and pain have been shown to be closely
associated in RA, but treatment does not always
impact these symptoms to the same extent
[21, 22]. In our analysis, treatment-related
improvements in pain accompanied improve-
ments in fatigue in most patients. Correlation
between fatigue and pain, however, was mod-
erate, reflecting the multifactorial nature of
fatigue. A small positive association between
reductions in fatigue and improvements in
sleep quality was also observed. Poor sleep has
been found to be significantly correlated to
general and mental fatigue reported by patients
with RA [23]. However, it is clear that sleep
quality is not the main driver of fatigue in RA.
Fatigue experienced by patients with RA can
be strongly related to disease activity as assessed
using DAS28 [24], and improvements in fatigue
with treatment have been shown to correlate
with reductions in disease activity [22]. Exami-
nation of the relationship between fatigue and
disease activity in biologic-naı¨ve patients with
RA initiating TNF-inhibitor therapy found that
approximately half of the effect on fatigue
associated with reduction in clinical symptoms
(measured by DAS28 [CRP]) was indirect,
mediated through a reduction in pain [25]. In
this analysis, improvement in fatigue with
abatacept treatment showed only a small asso-
ciation with DAS28 (CRP), possibly due to an
indirect effect through improvement in health
status.
These data should be interpreted within the
context of the limitations of the analysis. This
was a post hoc analysis of RCTs into which were
recruited a high proportion of patients with
poor prognosis and who were seropositive for
rheumatoid factor and/or anti-cyclic citrulli-
nated peptide. In addition, it should be noted
that a numerical rating scale was used to mea-
sure fatigue in this analysis, whereas the
Functional Assessment of Chronic Illness
Therapy-Fatigue (FACIT-F) [26] may be a more
useful tool to explore the multidimensional
nature of fatigue reported by patients with RA.
An additional limitation was that sleep data
were only available for two trials (AIM and
ATTAIN). Of note, no longitudinal analyses
were performed in the present study, which is a
limitation.
CONCLUSIONS
In this post hoc analysis, abatacept treatment
led to a rapid improvement in fatigue and pain
in most patients with RA, irrespective of disease
duration. Given the small to moderate associa-
tions observed between the effect of abatacept
on fatigue and effects on pain, sleep, and disease
activity, our analysis suggests the pathways
underlying these outcomes often represent dif-
ferent domains of response in RA. An increased
understanding of the complex nature and
underlying causes of fatigue in RA will inform
its management and potentially improve
health-related quality of life for many patients.
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